RecruitingPhase 1Phase 2NCT04887792

Acetazolamide for Treatment Resistant Schizophrenia

A Randomized Controlled Trial of Acetazolamide for Patients With Treatment Resistant Schizophrenia


Sponsor

Vishwajit Nimgaonkar, MD PhD

Enrollment

60 participants

Start Date

Feb 1, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

This is a double blind adjunctive randomized controlled trial for schizophrenia using acetazolamide.


Eligibility

Min Age: 18 YearsMax Age: 55 Years

Plain Language Summary

Simplified for easier understanding

This trial is testing whether a medication called acetazolamide (commonly used for altitude sickness and glaucoma) can help people with schizophrenia whose symptoms have not improved despite trying multiple antipsychotic drugs. Researchers want to know if it can be a useful add-on treatment. **You may be eligible if...** - You are between 18 and 55 years old - You have schizophrenia with significant ongoing symptoms (positive symptoms like hallucinations or delusions) despite trying at least two different antipsychotic medications - You have been on a stable dose of your current antipsychotic for more than 1 month - You are not currently enrolled in another clinical trial **You may NOT be eligible if...** - You have used substances or have a substance dependence recently (past month or 6 months) - You have epilepsy or other unstable neurological conditions - You are pregnant - You have kidney problems, Addison's disease, or certain types of glaucoma - You have ever taken acetazolamide or are allergic to it - You have an intellectual disability Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAcetazolamide

ACZ 250 mg/day in gelatin capsules will be administered initially and increased over 7-10 days to 2g/day.

DRUGPlacebo

Identical gelatin capsules will be prepared by filling with inert excipients.


Locations(2)

University of Pittsburgh

Pittsburgh, Pennsylvania, United States

St John's Medical College Hospital

Bangalore, India

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04887792


Related Trials